Application and the Production of Radiopharmaceutical's

Balaji.B.Ingle[1], Irshad.A.Shaikh.[2], Shyamlila B. Bavage[3],Nandkishor B. Bavage[4],
[1]*B.Pharmacy Final Year Student, Latur College of Pharmacy, Hasegaon, Tq. Ausa, Dist. Latur-413512, Maharashtra, India*
[2]*Department of Pharmaceutical Analysis, Latur College of Pharmacy Hasegaon, Tq. Ausa, Dist.Latur-413512 Maharashtra, India*
[3]*Department of Pharmacognosy and Toxicology, Latur College of Pharmacy Hasegaon, Tq. Ausa, Dist. Latur-413512 Maharashtra, India*
[4]*Department of Pharmaceutical Chemistry, Latur College of Pharmacy Hasegaon, Tq. Ausa, Dist. Latur-413512 Maharashtra, India*

***Abstract* - Radiopharmaceuticals are made of radioactive materials called radioisotopes. Radiopharmaceuticals are exclusive pharmaceutical preparations containing radioisotopes and are used in research, diagnosis or treatment in major clinical fields. They are radioactive reagents used in the field of nuclear medicine, which can show high and precise localized radioactivity in target tissues. However, recently with the emergence of some new radionuclides and radiopharmaceuticals for the treatment of cancer, neuroendocrine disorders and other diseases, this sector of nuclear medicine has made considerable progress. The establishment of radiopharmaceuticals is for the diagnosis and treatment of thyroid cancer, hyperthyroidism, bone pain metastasis, renal insufficiency, heart and brain perfusion and many other diseases. Radioactive materials can also be used to sterilize heat-labile materials, such as syringes, catheters, vitamins, hormones, and surgical dressings. The field of nuclear medicine has the advantages of tumor localization, safe diagnosis, no accumulation of radiation, and high therapeutic effect. This review focuses on the production and therapeutic application of radiopharmaceuticals containing functional radioactive atoms.**

***Index Terms* - Radionuclides, Radio- active decay, nuclear medicine, Compounding of radiopharmaceuticals.**

INTRODUCTION

The basic principles of molecular biology, immunology, and genetics have produced many major improvements. In addition to detecting molecules and drugs related to diseases that are mainly targeted at diseases, they have also contributed to the introduction and development of tumors, heart diseases, and neurological diseases. Recognition puts pressure on. cell therapy. These looms gave birth to the development of targeted radiopharmaceuticals and demonstrated new aspects of radiopharmaceuticals in nuclear medicine. 1 Compared with other drugs and medicinal products, radiopharmaceuticals have a short history. The widespread use of radionuclides in medical applications is a direct result of the development of the atomic bomb during World War II. The construction of nuclear reactors in this context opens up the possibility of generating a wide range of new radionuclides through neutron activation of non-radioactive targets. Radionuclides not found in nature can now be produced artificially, and their quantities can be used for scientific and medical applications. 1 Significant change have taken place in the management of healthcare in many Western countries in the 1990s. From basically unconstrained resources, open budgets, and complete clinical freedom, healthcare provision has become a highly controlled established agreement, tight budget, and internal market. Drug development is also subject to stricter supervision. Radiopharmaceuticals must now comply with all regulations governing conventional drugs, which greatly increase their development costs. With industry mergers and acquisitions, the number of major commercial radiopharmaceuticals in this field is also declining, limiting the possibility of commercial development of academic discoveries. Institutions engaged in the development of radiopharmaceuticals also experienced major disruptions2. The difference between radiopharmaceuticals and ordinary drugs is that they have a short half-life. Due to their rapid decomposition, they must be prepared shortly before clinical use, and total quality control (QC) of the final product is impossible: for example, sterility testing cannot be performed due to time constraints. Therefore, the safe and effective preparation and use of radiopharmaceuticals is essential to protect operators and end users, namely patients. The use of radioactive materials requires trained and approved personnel to use these products carefully and safely; in accordance with the guidelines of the Indian Atomic Energy Regulatory Commission (AERB), in licensed/approved laboratory facilities.

DEFINATIONS AND TERMINOLOGY

RADIONUCLIDE

Nuclides having an unstable arrangement of protons and neutrons that alter unexpectedly to either a stable or another unstable mixture of protons and neutrons with a steady statistical possibility by releasing radiation. These are believed to be radioactive and are called radionuclides. The initial unstable nuclide is said as the ‘parent radionuclide’ and the nuclide after alteration as the ‘daughter nuclide’. Such a conversion is also known as ‘Radioactive transmutation’ or ‘radioactive disintegration’ or ‘radioactive decay’

Units of Radioactivity

In the International System (SI), the radioactive unit is a nuclear transmutation every second, denoted by becquerel (Bq) and named after the scientist Henri Bequerel. The old unit of radioactivity was Curie (Ci), named after Marie Curie and Pierre Curie, pioneer scientists who studied radioactive phenomena. 1 Ci is the decay number emitted from 1 g Radio-226, which is equal to 3.7 x 1010 Bq. Absolute radioactivity measurement requires specialized laboratories, but the identification and measurement of radiation can be compared with standardized preparations provided by reference laboratories recognized by international or national authorities.

Half-Life Period

The time in which a given quantity of a radionuclide decays to half its initial value is termed as half-life (T1/2).

Isotope carriers are stable isotopes of elements present in or added to radioisotopes of the same element. Radionuclides usually contain isotope carriers, the content of which depends on the route/method of producing the radionuclide.

Specific radioactivity

The radioactivity of a radionuclide per unit mass of the element or of the chemical form of the radioactive preparation is referred to as the ‘Specific Radioactivity’; sometimes also referred as ‘specific activity’.

Total radioactivity

The radioactivity of the radionuclide per unit of the dispensed formulation (vial, capsule, ampoule, generator, etc) is the total radioactivity, which is an important parameter in dispensing and administration of the radioactive material to the patient as well as from the regulatory requirement for safe handling of the radioactive materials in a facility.

Radionuclide Generator

A radioisotope generator is an ion exchange column containing resin or alumina in which a remote parent nuclide is inserted. A typical radionuclide glass or plastic column and under this is full of advertising material in which the parent nuclide is advertised. After the equilibrium present after a 4–5 half-life, the daughter's nuclide growth has been shown in a highly loaded area with a suitable solvent. It includes the production of 68Ga, 82Rb, 99mTc and 113mI radionuclides, of which 99mTc is the most important. Due to its optimal thinking ability and part of the physical life and ability to bind to many chemicals, about 85% of all thought processes are performed following 99mTc administration.

Production of Radionuclides

Radionuclides used in radiopharmaceuticals are produced by decomposing radiation of other explosive atoms. This product can be made in any of the following ways.

Radioisotope produced by Thermal Neutron Reactor

In radioactive radioisotopes produced by neutrons, the reactor is a source of hot neutrons. The reaction of (n, gamma) occurs. It causes an increase in the weight of each atom and no change in the number of atoms. The same thing exists. 7 Eg. 98Mo after response produces 99Mo.

Frequently Used Radiation Sources

There are many sources of radiation used in the health care system. The difference is related to the location of the radiation source; External radiation therapy is outside the body, brachytherapy uses closed radioactive sources directly into the treated area and systemic radioisotopes are given orally or orally.

Virtual Simulation and 3-Dimensional Radiation Therapy

Radiation therapy has been modified with the ability to process nearby tissue and general structures up to three sizes using CT and / or MRI scans and editing software. Visual simulation, which is a basic form of planning, allows for more accurate placement of radiation than normal X-rays, where soft tissue structures are often difficult to diagnose and normal tissue is difficult to protect.

Auger Treatment

Auger Therapy (AT) uses a very high dose of ionizing radiation in situ that provides molecular conversion of atomic scales. AT differs from conventional radiation therapy in several respects; does not rely on radioactive nuclei to cause cell-based radiation damage, nor does it share multiple external pencil beams from different directions to zero-in to bring volume to the target at a reduced volume outside the target tissue / organs. Instead, in-situ delivery of the highest dose at the cellular level using AT aims Kar et al.: Production and Applications of Radiopharmaceuticals: A Review International Journal of Pharmaceutical Investigation, Vol 9, Issue 2, Apr-Jun 2019 39 in situ cell repair involving cell breaking and cell remodeling as stem cell modification and cellular cellular functions associated with these molecule structures.16

Nuclear Medicine

Nuclear medicine is a medical diagnostic tool for imaging metabolism and other processes that work in the human body. Prior to the photography procedure a patient with a radio label is taken. The power of this process depends on how things move in organ systems in the most selective ways. Labeling these objects on radioactive tracks (especially technetium) enables the imagination of the distribution of such substances in the human body with the help of gamma cameras or PET scanners. Three different methods are available for this procedure: planar scintigraphy, SPECT (single photon emission computed tomography) and PET (positron emission tomography) .23

Internal Treatment

Direct intra-cavitary administration is a delivery method for radiopharmaceuticals with high concentration in tumors spread over serosal linings of cavities and tumors cell presents in malignant effusions. To reduce radionuclide leakage in the cavity, it is usually given in the form of a radio colloid. Internal therapy is applied to the peritoneal, pleural and pericardial cavities as well as cystic brain tissues and spinal cord. Colloidal 198Au was previously the most widely used agent, but radionuclide emits unwanted gamma rays, resulting in unnecessary exposure to unintended tissue within the patient. Optional agents are now 32P and 90Y colloids, which are likely to be widely used antibodies written by the radio in the future.

Thinking of the Heart

Radiopharmaceuticals help with cardiovascular thinking as agents that provide information on the chemistry of blood chemistry in the region. There is a provision to provide information on major cardiac output. The study involves compressing the patient by exercising on a treadmill or by giving an iv. dipyridamole injection. An injection of thallium chloride or technetium-99m (99mTc) labeled methoxy isobutyl isonitrile is given a picture is made.29

Illustration of the Brain

Brain imaging is performed using radiopharmaceuticals with single photon emission computed tomography (SPECT) and positron emission tomography (PET). SPECT and PET radiopharmaceuticals are distinguished by the presence of blood-brain-barrier (BBB), cerebral infiltration and metabolism receptor-binding and antigen antibody binding. SPECT agents circulating blood vessels, such as 99mTc-DTPA, 201Ti and 67Ga-citrated are released by normal brain cells but enter the tumor cell due to the altered BBB. The incorporation of radiopharmaceuticals into tumor cells was rapid and hot and pH dependent. The concentration of radioactivity in tumor cells varied from 10 to 33% of total activity following 30 min at 37 ° (pH 7.4). In comparison, the accumulation of radiopharmaceuticals in normal brain and pancreatic tissue remains very low. Imaging brain tissue requires a disturbed BBB, however, it is strong in the early stages of brain tumor growth, where diagnosis is very important. In relation to normal brain, tumor brain cells are often higher than audible peptide receptors, such as the epidermal growth factor (EGF) receptor. Peptide radiopharmaceuticals such as EGF-labeled radio can be used to illustrate primary brain tissue

Orthopedic Treatment

Bone metastases are commonly found in patients with prostate, breast and lung cancer and in these patients controlling bone pain is a major clinical problem. The radius of the external beam, combined with analgesic drugs, remains a pillar of treatment but the value of the untreated body is limited. Many beta-releasing radionuclides, in a variety of chemical compounds, can be used to treat bone metastases. 32P, 89Sr, 186-Rhenium and 153-Samaraum made

Benefits of Radiopharmaceuticals in Healthcare System

It can be used as a diagnostic and treatment of the patient.

It can provide a quick start to pain relief.

It is common to treat cancer.

It can cure many diseases.

Extensive treatment mode.

Direct treatment of the tumor, especially useful for bone metastasis.

The same dose applies to other patients. • Nuclear medicine tests can be done on children. • Nuclear medicine procedures have no side effects and are completely safe.42

Negative Radiopharmaceuticals in the Health Care System

When given in large quantities, it may present long-term disruption and discomfort to patients.

Excessive radiation of the head and neck may be associated with heart problems, thyroid dysfunction and pituitary axis dysfunction.

Nuclear medicine tests are not recommended for pregnant women, because unborn babies are more sensitive to radiation than children or adults.

Filling in patients' teeth, toothpicks and permanent bridges can cause some problems in the mouth.

It can produce allergies.

It is dangerous for radiation.

Myelosupression is possible, especially with previous chemotherapy.43

CONCLUSION

These days there are different types of radiation radiopharmaceuticals available and that play an important role in diagnosing diseases. Recently, however, there has been significant growth in the branch of nuclear medicine with the introduction of new radionuclides and radiopharmaceuticals in the treatment of bone pain, neuroendocrine and other tumors. Today the field of radionuclide therapy goes through a very interesting and exciting phase and is ready for great growth and development in the years to come.

REFERENCES

[1] Markus M, Wolfgang W. Imaging Biomarkers or Biomarker Imaging?. Pharmaceuticals. 2014;7(7):765-78. doi:10.3390/ph7070765

[2] Venugopal V. Societal Application of Nuclear Technology in health care, Industry and Water Resource Management in India. Energy Procedia. 2011;7:553-9.

[3] Reetesh M, Richa B, Sonam J. A Review on Therapeutic Approach of Radiopharmaceutical in Health Care System. International Journal of Pharmaceutical and Biological Archives. 2012;3(3):487-92.

[4] Frank R. Radiochemistry and Radiopharmaceutical Chemistry for Medicine. Radiochemistry and Nuclear Chemistry: Encyclopedia of life support systems and UNESCO. 2010;2:63-94.

[5] Chourasia MK, Ashawat MS, Neeti J, Chalasani KB, Jain RK, Sabitha M, et al. Radiopharmaceuticals: Preparation, Evaluation and Application, Indian. J Pharm Science. 2003;65(5):439-49.

[6] Vera-Rulz H. Radiopharmaceuticals as therapeutic agents in Medical care and Treatment: A new IAEA research programme assists countries interested in the use of improved radiopharmaceuticals for medical therapy. IAEA Bulletin. 1993;35(1):24-7.

[7] Sudipta C, Vimalnath KV, Rajeswari A, Ajit S, Sharma HD, Kamaleswaran K, et al. Preparation, Evaluation and first clinical use of 177Lu – Labeled hydroxyapatite particles in the treatment

of Rheumatoid arthritis: Utility of cold kits for convenient dose formulation at hospital radio-pharmacy. J Label Compd Radiopharm. 2014;57(7):453-62.

[8] Reetesh M, Richa B, Sonam J. A Review on Therapeutic Approach of Radiopharmaceutical in Health Care System. Int J Pharma and Bio Archi. 2012;3(3):487-92.

[9] Wynn AV, Timothy JH. Therapeutic Radiopharmaceuticals. Chem Rev. 1999;99(9):2269-92. 10. Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med. 2011;52(6):841-4. 11. Graham MM. Clinical molecular imaging with radiotracers: Current status. Med rinc Pract. 2012;21(3):197-208.

[10] Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med. 2011;52(6):841-4. 11. Graham MM. Clinical molecular imaging with radiotracers: Current status. Med Princ Pract. 2012;21(3):197-208.

[11] Aerts A, Impens N, Gijs M, D'Huyvetter M, Vanmarcke H, Ponsard B, et al. Biological Carrier Molecules of Radiopharmaceuticals for Molecular Cancer Imaging and Targeted Cancer Therapy. Curr Pharm Des. 2014;20(32):5218-44.

[12] Asabella AN, Cascini GL, Altini C, Paparella D, Notaristefano A, Rubini G, et al. The copper radioisotopes: A systematic review with special interest to 64Cu. Biomed Res Int. 2014;786463.

[13] Attard AR, Chappell MJ, Bradwell AR. Model based calculation for effective cancer radioimmunotherapy. Br J Radiol. 1995;68(810):636-45.

[14] Baczyk M, Czepczynski R, Milecki P, Pisarek M, Oleksa R, Sowinski J. 89Sr versus 153Sm-EDTMP: Comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun. 2007;28(4):245-50.

[15] Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: Targeted alpha-particle radiation therapy. Clin Cancer Res. 2013;19(3):530-7.

[16] Barbet J, Bardies M, Bourgeois M, Chatal JF, Cherel M, Davodeau F, et al. Radiolabeled antibodies for cancer imaging and therapy. Methods Mol Biol. 2012;907:681-97.

[17] Bayouth JE, Macey DJ, Kasi LP, Garlich JR, McMillan K, Dimopoulos MA, et al. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med. 1995;36(5):730-7.

[18] Blumgart HL, Yens OC. Studies on the velocity of blood flow: I. The method utilized. J Clin Invest. 1927;4(1):1-13.

[19] Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, Bartolomei M, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm. 2004;19(1):65-71.

[20] Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O'Dorisio MS, et al. The joint IAEA, EANM and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800-16.

[21] Bolzati C, Boschi A, Uccelli L, Tisato F, Refosco F, Cagnolini A, et al. Chemistry of the strong electrophilic metal fragment [(99) Tc(N)(PXP)](2+) (PXP = diphosphine ligand): A novel tool for the selective labeling of small molecules. J Am Chem Soc. 2002;124(38):11468-79.

[22] Boschi A, Bolzati C, Uccelli L, Duatti A, Benini E, Refosco F, et al. A class of asymmetrical nitrido 99mTc heterocomplexes as heart imaging agents with improved biological properties. Nucl Med Commun. 2002;23(7):689-93.

[23] Boschi A, Uccelli L, Bolzati C, Duatti A, Sabba N, Moretti E, et al. Synthesis and biologic evaluation of monocationic asymmetric 99mTc-nitride heterocomplexes showing high heart uptake and improved imaging properties. J Nucl Med. 2003;44(5):806-14.

[24] Boyd GS, Merrick MV, Monks R, Thomas IL. Se-75 Labeled bile acid analogs, new radiopharmaceuticals for investigating the enterohepatic circulation. J Nucl Med. 1981;22(8):720-5